WellSpring Pharmaceutical Corporation Emetrol(R) Consumer Brand Achieves Number One Position in Anti-Nausea Category

SARASOTA, Fla., April 21 /PRNewswire/ -- WellSpring Pharmaceutical Corporation announced earlier today that Emetrol (R), its liquid anti-nausea brand is now the leading product in its category. Based on trailing 52 weeks sales (ending 1/14/09) Emetrol(R) garnered 51.7 % of the brand category displacing all others including private label. The most recent IRI reports indicate that Emetrol (R) sales are up 24% over last year reflecting the fact that it is recommended by name by OB/GYN’s, Pediatricians and Pharmacists. Over 90% of OB/GYN’s interviewed indicate that they would most likely use Emetrol(R) as first line therapy in treating mild to moderate nausea.

For over 60 years, Emetrol(R) has provided consumers with reliable relief from nausea and vomiting. Emetrol (R) is popular with more and more consumers including women between the ages of 25 and 34 who seek Emetrol(R) due to their doctor or pharmacist’s recommendation. Emetrol(R) is specifically recommended because it is safe, effective, and gives fast relief from nausea and vomiting due to upset stomach, flu, and food indiscretions. WellSpring has rolled out a national advertising campaign targeting this population segment. And the National Association of Pediatric Nurse Practitioners (NAPNAP) has selected Emetrol(R) for editorial content in their upcoming issue which reaches 3.5 million women ages 25-48.

WellSpring’s President and CEO, Dr. Robert A. Vukovich commented on this announcement: “The Emetrol(R) brand is an important one for our company as we have seen remarkable growth in its sales over this past year. The fact that we are recommended by OB/GYN physicians for their patients experiencing nausea associated with pregnancy and by Pediatricians for children under their care, has proven to be one of the most important attributes of the brand. Containing a unique combination of phosphorylated carbohydrates Emetrol (R) is considered by these physicians as safe and effective for treating mild to moderate nausea. We will continue to invest heavily in the brand with a new national advertising campaign.”

WellSpring Pharmaceutical Corporation is a closely held pharmaceutical company marketing both prescription and non-prescription consumer drug brands. The firm has headquarters in Sarasota, Florida and operates a state-of-the-art GMP compliant manufacturing facility in Canada.

Emetrol Website: www.emetrol.com

CONTACT: Wendy Shusko, COO, +1-941-312-4727, Wayne Miller, VP Sales,
+1-941-312-4727, both of WellSpring Pharmaceutical Corporation

Web site: http://www.emetrol.com/